OnKure Therapeutics, Inc.

Contributing Author

Recent Articles by OnKure Therapeutics, Inc.

Jul-02	OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Ka Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 OKUR GlobeNewswire
May-05	OnKure Therapeutics Reports First Quarter 2026 Financial Results OKUR OKUR -9.96% GlobeNewswire
Mar-27	OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Ka Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies OKUR -13.07% GlobeNewswire
Mar-12	OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results OKUR OKUR +7.39% GlobeNewswire
Nov-06	OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update OKUR +5.33% OKUR -6.96% GlobeNewswire
Nov-04	OnKure Therapeutics to Participate in Upcoming Investor Conferences OKUR -5.20% GlobeNewswire
Aug-12	OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update OKUR OKUR +20.00% GlobeNewswire
May-06	OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights OKUR -11.16% GlobeNewswire